{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:41:28Z","timestamp":1722991288187},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,5]]},"DOI":"10.7759\/cureus.66221","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T01:08:31Z","timestamp":1722906511000},"source":"Crossref","is-referenced-by-count":0,"title":["Resolution of Breast Cancer in a Patient With Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor With the Combination of Chemotherapy and Lanreotide"],"prefix":"10.7759","author":[{"given":"Saki","family":"Komai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Harai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ippei","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichiro","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030687","article-title":"The TSH\/thyroid hormones axis and breast cancer","volume":"11","author":"Voutsadakis IA","year":"2022","unstructured":"Voutsadakis IA. The TSH\/thyroid hormones axis and breast cancer. J Clin Med. 2022, 11:10.3390\/jcm11030687","journal-title":"J Clin Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1258\/0004563011900993","article-title":"Endocrinology of gynaecomastia","volume":"38","author":"Ismail AA","year":"2001","unstructured":"Ismail AA, Barth JH. Endocrinology of gynaecomastia. Ann Clin Biochem. 2001, 38:596-607. 10.1258\/0004563011900993","journal-title":"Ann Clin Biochem"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.6.7593","article-title":"Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas","volume":"86","author":"Caron P","year":"2001","unstructured":"Caron P, Arlot S, Bauters C, et al.. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001, 86:2849-53. 10.1210\/jcem.86.6.7593","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023","volume":"21","author":"Gradishar WJ","year":"2023","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al.. NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023, 21:594-608. 10.6004\/jnccn.2023.0031","journal-title":"J Natl Compr Canc Netw"},{"key":"ref5","article-title":"Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer","volume":"34","author":"Frati A","year":"2014","unstructured":"Frati A, Rouzier R, Lesieur B, et al.. Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer. Anticancer Res. 2014, 34:3997-4003.","journal-title":"Anticancer Res"},{"key":"ref6","article-title":"Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies","volume":"4","author":"Schulz S","year":"1998","unstructured":"Schulz S, Schulz S, Schmitt J, et al.. Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res. 1998, 4:2047-52.","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2755","article-title":"Phosphorylated insulin-like growth factor-i\/insulin receptor is present in all breast cancer subtypes and is related to poor survival","volume":"68","author":"Law JH","year":"2008","unstructured":"Law JH, Habibi G, Hu K, et al.. Phosphorylated insulin-like growth factor-i\/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008, 68:10238-46. 10.1158\/0008-5472.CAN-08-2755","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s41181-017-0030-z","article-title":"Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?","volume":"2","author":"Dalm SU","year":"2017","unstructured":"Dalm SU, de Jong M. Comparing the use of radiolabeled SSTR agonists and an SSTR antagonist in breast cancer: does the model choice influence the outcome?. EJNMMI Radiopharm Chem. 2017, 2:11. 10.1186\/s41181-017-0030-z","journal-title":"EJNMMI Radiopharm Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S39987","article-title":"A review of the use of somatostatin analogs in oncology","volume":"6","author":"Keskin O","year":"2013","unstructured":"Keskin O, Yalcin S. A review of the use of somatostatin analogs in oncology. Onco Targets Ther. 2013, 6:471-83. 10.2147\/OTT.S39987","journal-title":"Onco Targets Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000049162","article-title":"Management of breast cancer: is there a role for somatostatin and its analogs?","volume":"47 Suppl 2","author":"Boccardo F","year":"2001","unstructured":"Boccardo F, Amoroso D. Management of breast cancer: is there a role for somatostatin and its analogs?. Chemotherapy. 2001, 47 Suppl 2:62-77. 10.1159\/000049162","journal-title":"Chemotherapy"},{"key":"ref11","article-title":"NCCN guidelines for patients: metastatic breast cancer","year":"2024","unstructured":"NCCN guidelines for patients. metastatic breast cancer. Internet. 2024, Accessed: May 7, 2024: https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/stage_iv_breast-patient.pdf.."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-2414-0","article-title":"Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology","volume":"92","author":"Kumar U","year":"2005","unstructured":"Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat. 2005, 92:175-86. 10.1007\/s10549-005-2414-0","journal-title":"Breast Cancer Res Treat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/BF01806354","article-title":"Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients","volume":"15","author":"Ciocca DR","year":"1990","unstructured":"Ciocca DR, Puy LA, Fasoli LC, et al.. Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res Treat. 1990, 15:175-84. 10.1007\/BF01806354","journal-title":"Breast Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2009.59","article-title":"The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells","volume":"30","author":"He Y","year":"2009","unstructured":"He Y, Yuan XM, Lei P, et al.. The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin. 2009, 30:1053-9. 10.1038\/aps.2009.59","journal-title":"Acta Pharmacol Sin"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-015-0291-7","article-title":"The role of the insulin-like growth factor-1 system in breast cancer","volume":"14","author":"Christopoulos PF","year":"2015","unstructured":"Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer. 2015, 14:43. 10.1186\/s12943-015-0291-7","journal-title":"Mol Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/mp.54.3.149","article-title":"Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects","volume":"54","author":"Dupont J","year":"2001","unstructured":"Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol. 2001, 54:149-54. 10.1136\/mp.54.3.149","journal-title":"Mol Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ20-0707","article-title":"Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan","volume":"68","author":"Shimatsu A","year":"2021","unstructured":"Shimatsu A, Nakamura A, Takahashi Y, et al.. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan. Endocr J. 2021, 68:791-805. 10.1507\/endocrj.EJ20-0707","journal-title":"Endocr J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz SA","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung WP, et al.. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023, 401:105-17. 10.1016\/S0140-6736(22)02420-5","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.02.002","article-title":"Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis","volume":"102","author":"Dasgupta P","year":"2004","unstructured":"Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004, 102:61-85. 10.1016\/j.pharmthera.2004.02.002","journal-title":"Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.01.006","article-title":"Biology of somatostatin in breast cancer","volume":"286","author":"Watt HL","year":"2008","unstructured":"Watt HL, Kharmate G, Kumar U. Biology of somatostatin in breast cancer. Mol Cell Endocrinol. 2008, 286:251-61. 10.1016\/j.mce.2008.01.006","journal-title":"Mol Cell Endocrinol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/275883-resolution-of-breast-cancer-in-a-patient-with-thyroid-stimulating-hormone-secreting-pituitary-neuroendocrine-tumor-with-the-combination-of-chemotherapy-and-lanreotide","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T01:08:37Z","timestamp":1722906517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/275883-resolution-of-breast-cancer-in-a-patient-with-thyroid-stimulating-hormone-secreting-pituitary-neuroendocrine-tumor-with-the-combination-of-chemotherapy-and-lanreotide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.66221","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,5]]}}}